AML (Acute Myeloid Leukemia) Clinical Trials

11 recruitingLast updated: June 18, 2026

There are 11 actively recruiting aml (acute myeloid leukemia) clinical trials across 5 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 4. Top locations include St Louis, Missouri, United States, New York, New York, United States, Beijing, China. Updated daily from ClinicalTrials.gov.


AML (Acute Myeloid Leukemia) Trials at a Glance

11 actively recruiting trials for aml (acute myeloid leukemia) are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in St Louis, New York, and Beijing. Lead sponsors running aml (acute myeloid leukemia) studies include BlueSphere Bio, Inc, Chongqing Precision Biotech Co., Ltd, and Beijing 302 Hospital.

Browse aml (acute myeloid leukemia) trials by phase

Treatments under study

About AML (Acute Myeloid Leukemia) Clinical Trials

Looking for clinical trials for AML (Acute Myeloid Leukemia)? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new AML (Acute Myeloid Leukemia) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about AML (Acute Myeloid Leukemia) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Not Applicable

Haplo-Cord HSCT for AML/MDS

MDS (Myelodysplastic Syndrome)AML (Acute Myeloid Leukemia)
Fujian Medical University Union Hospital82 enrolled4 locationsNCT07588360
Recruiting
Phase 4

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

CholangiocarcinomaSolid Tumor MalignanciesGlioma+1 more
Rigel Pharmaceuticals16 enrolled2 locationsNCT07486713
Recruiting
Phase 2

Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS

MDS (Myelodysplastic Syndrome)AML (Acute Myeloid Leukemia)
Ruijin Hospital20 enrolled1 locationNCT07607418
Recruiting
Phase 1

Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

AML, Adult RecurrentAML (Acute Myeloid Leukemia)AML With Mutated NPM1
BlueSphere Bio, Inc19 enrolled1 locationNCT07566585
Recruiting
Phase 2

VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial

AML (Acute Myeloid Leukemia)
Beijing 302 Hospital48 enrolled1 locationNCT07514832
Recruiting

WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing Treatment

MDS (Myelodysplastic Syndrome)AML (Acute Myeloid Leukemia)
University of Oxford80 enrolled1 locationNCT07511829
Recruiting
Phase 1

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Chronic Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia (CMML)+1 more
Crossbow Therapeutics, Inc.72 enrolled11 locationsNCT06994676
Recruiting
Phase 2

Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML

AML (Acute Myeloid Leukemia)Allogeneic Hematopoietic Cell Transplantation (HCT)
Institute of Hematology & Blood Diseases Hospital, China134 enrolled5 locationsNCT07304232
Recruiting

Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX

AML (Acute Myeloid Leukemia)
Clinical Hub for Interventional Research (CHOIR)25 enrolled4 locationsNCT06782971
Recruiting
Phase 2

Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

AML (Acute Myeloid Leukemia)
Technische Universität Dresden60 enrolled1 locationNCT06696183
Recruiting
Phase 1

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN

AML (Acute Myeloid Leukemia)BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm)
Chongqing Precision Biotech Co., Ltd30 enrolled1 locationNCT06690827